BridgeMD
COMeBAC- COMparison between Bensypenicillin And Cloxacillin treatment in PSSA
EU CTIS ID: 2023-506860-15-00
What this study is testing
Compare clinical outcome in patients with penicillin susceptible Staphylococcus aureus bacteraemia treated with bensylpenicillin compared to cloxacillin.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- > 18 years with penicillin susceptible S. aureus bacteraemia
- Abiliaty to give informed consent
You likely can't join if
- Allergy to penicillin
- More than one significant bacterial species in blood cultures.
- ≥ 96h of antibiotic treatment before inclusion
- Verified or strong suspicion of prosthetic joint infection
- Terminal ill patients with a suscpected survival less than 7 days
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.